Dry Powder Inhalers Linked to Fewer COPD Exacerbations vs. Other Types

For individuals managing chronic obstructive pulmonary disease (COPD), minimizing exacerbations – sudden worsenings of symptoms – is a primary goal of treatment. Recent research published in JAMA Internal Medicine suggests that the type of inhaler used to deliver long-acting medications may play a role in achieving this. Specifically, the study indicates a lower risk of moderate or severe COPD exacerbations among patients using dry powder inhalers compared to those using metered-dose or soft mist inhalers.

Dry Powder Inhalers and Reduced Exacerbation Risk

The study, led by researchers examining data from a large health insurance cohort, focused on new users of long-acting muscarinic antagonist-long-acting beta agonist (LAMA-LABA) inhalers. Researchers found that individuals initiating treatment with umeclidinium-vilanterol, a dry powder inhaler, experienced a significantly reduced risk of a first moderate/severe COPD exacerbation compared to those using glycopyrrolate-formoterol, a metered-dose inhaler. The hazard ratio was 0.86, meaning those on the dry powder inhaler had a 14% lower risk. This translated to a number needed to treat of 17 – meaning one exacerbation would be prevented for every 17 patients switched to the dry powder inhaler.

Interestingly, a comparison between umeclidinium-vilanterol and tiotropium-olodaterol, a soft mist inhaler, also showed a trend towards reduced risk with the dry powder inhaler, though the difference was smaller (hazard ratio of 0.97). A separate analysis directly comparing tiotropium-olodaterol to glycopyrrolate-formoterol showed a reduction in exacerbations with the soft mist inhaler as well (hazard ratio of 0.94).

“We have now seen across two studies that once-daily dry powder inhalers seem to be associated with slightly improved clinical outcomes compared to twice-daily metered dose inhalers,” explained William B. Feldman, MD, DPhil, MPH, associate professor of medicine at the David Geffen School of Medicine at UCLA, in an interview with Healio. Dr. Feldman noted the consistency of these findings across different study populations – one looking at new users of triple therapy (inhaled corticosteroid, LAMA, LABA) and the current study focusing on LAMA-LABA combinations.

Understanding the Inhaler Types

COPD medications are often delivered via inhalers, but these devices differ in how they release the medication into the lungs. Metered-dose inhalers (MDIs) release a measured dose of medication as a spray, requiring coordination between pressing the canister and inhaling. Soft mist inhalers (SMIs) deliver a slower-moving mist, potentially making it easier to inhale the medication deeply into the lungs. Dry powder inhalers (DPIs), deliver medication as a dry powder activated by a strong, fast inhalation.

The choice of inhaler can significantly impact medication delivery and, treatment effectiveness. Factors like inspiratory flow rate, coordination, and device technique can all influence how much medication reaches the lungs. DPIs, for example, require a forceful inhalation, which can be challenging for some individuals with COPD.

Study Methodology and Considerations

The research involved a retrospective analysis of claims data from a large commercial health insurance and Medicare Advantage plan. Researchers analyzed data from over 36,000 individuals aged 40 and older who were newly prescribed a LAMA-LABA inhaler. To minimize bias, they used propensity score matching to create comparable groups of patients based on various characteristics. This involved matching individuals using different inhaler types who had similar baseline health profiles.

While the study demonstrated a statistically significant reduction in exacerbation risk with dry powder inhalers, it’s essential to note that the absolute risk reduction was relatively tiny. The number needed to treat (NNT) values – 17 for the comparison with the metered-dose inhaler and 100 for the comparison with the soft mist inhaler – indicate that a considerable number of patients would necessitate to switch to a dry powder inhaler to prevent one additional exacerbation.

the study did not find significant differences in the risk of major adverse cardiovascular events, urinary tract infections, or pneumonia hospitalizations between the inhaler groups. This suggests that the observed benefits of dry powder inhalers are primarily related to COPD control and not an increased risk of other complications.

Environmental Impact and Future Directions

Beyond clinical outcomes, the choice of inhaler also has environmental implications. Metered-dose inhalers utilize propellants that are potent greenhouse gases, contributing to climate change. Dry powder and soft mist inhalers have a lower carbon footprint, making them a more environmentally sustainable option.

“We know that metered-dose inhalers are associated with higher greenhouse gas emissions than dry powder or soft mist inhalers,” Dr. Feldman emphasized. “But questions persist about the comparative effectiveness and safety of these products in different therapeutic classes.”

Looking ahead, Dr. Feldman suggests that further research is needed to confirm these findings and to explore the optimal inhaler choice for different COPD patients. He believes the current evidence supports considering dry powder or soft mist inhalers as part of a comprehensive COPD management plan.

For more information:

William B. Feldman, MD, DPhil, MPH, can be reached at [email protected].

It’s crucial for individuals with COPD to discuss their treatment options with a qualified healthcare professional to determine the most appropriate inhaler and management strategy based on their individual needs and circumstances. Regular monitoring and adherence to prescribed medications are essential for controlling COPD symptoms and improving quality of life.